DMARDs & Immunosuppressives

FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA

October 9, 2020 • By Michele B. Kaufman, PharmD, BCGP

Janus Kinase vs. TNF Inhibitors: The Context for Venous Thromboembolism Risk with RA Treatments

October 7, 2020 • By Larry Beresford

RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement

October 1, 2020 • By Arthritis & Rheumatology

Oxford University to Study Adalimumab as Potential COVID-19 Treatment

September 30, 2020 • By Josephine Mason & Kate Kelland

U.S. & E.U. Differ on Filgotinib for RA

September 14, 2020 • By Michele B. Kaufman, PharmD, BCGP

Biologics May Prevent Cardiovascular Events in RA Patients

August 26, 2020 • By Arthritis & Rheumatology

Guselkumab Approved for PsA

August 6, 2020 • By Michele B. Kaufman, PharmD, BCGP

FDA Approves Secukinumab for Non-Radiographic Axial Spondyloarthritis

August 5, 2020 • By Michele B. Kaufman, PharmD, BCGP

Study Compares Ixekizumab with Ustekinumab for the Treatment of Nail Psoriasis

August 4, 2020 • By Michele B. Kaufman, PharmD, BCGP

Ixekizumab May Improve Pain & Sexual Health in Patients with Genital Psoriasis

July 14, 2020 • By Michele B. Kaufman, PharmD, BCGP